Previous 10 | Next 10 |
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction , today announced that m...
Axonics Modulation Technologies (AXNX) Q4 2018 Earnings Conference Call March 05, 2019 04:30 PM ET Company Participants Matt Clawson - W2O Group, Investor Relations Ray Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Karen Noblett - Chief Me...
Axonics Modulation Technologies (NASDAQ: AXNX ): Q4 GAAP EPS of -$0.50 misses by $0.14 . More news on: Axonics Modulation Technologies, Earnings news and commentary, Healthcare stocks news, Read more ...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction , reported today financi...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction , today announced that Mi...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction , today announced the sub...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction , announced today that i...
Thinly traded Axonics Modulation Technologies ( AXNX +9.2% ) is up on modestly higher volume following its announcement of positive results from a pivotal study, ARTISAN-SNM , evaluating its implantable Axonics r-SNM neuromodulator for the treatment of urinary urgency incontinence. Mo...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction , disclosed today positiv...
Axonics Modulation Technologies (NASDAQ: AXNX ) has submitted complete test data to FDA for the purpose of gaining Conditional Full Body Magnetic Resonance Imaging (“MRI”) labeling approval for the Axonics r-SNM System for urinary and bowel dysfunction. More news on: A...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...